A two-pronged HER2 antibody beat the standard first treatment in HER2+ breast cancer
In a phase 3 trial in China published Oct. 24, 2026, in NEJM, 58.5% of women with HER2-positive advanced breast cancer on anbenitamab plus a docetaxel formulation were free of progression at…